Observational Study of BIS in Hemodialysis Patients

Sponsor
ImpediMed Limited (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05381961
Collaborator
California Institute of Renal Research (Other), Frenova Renal Research (Other)
70
2
2.9
35
12.2

Study Details

Study Description

Brief Summary

This observational study will evaluate bioimpedance spectroscopy (BIS) measurements from patients undergoing hemodialysis.

Condition or Disease Intervention/Treatment Phase
  • Device: Bioimpedance spectroscopy (BIS) measurement, SOZO device

Detailed Description

This observational study will evaluate bioimpedance spectroscopy (BIS) measurements from patients undergoing hemodialysis. If changes in BIS parameters correlate with changes in fluid volume and patient symptoms, BIS may help provide a non-invasive way to estimate the amount of fluid to dialyze during a hemodialysis session. Data from this study may be used to inform the design of a future interventional trial of BIS use in hemodialysis patients.

Study Design

Study Type:
Observational
Anticipated Enrollment :
70 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Observational Study of Bioimpedance Spectroscopy (BIS) for Use in a Renal Population
Actual Study Start Date :
Apr 4, 2022
Anticipated Primary Completion Date :
Jun 30, 2022
Anticipated Study Completion Date :
Jun 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Stable hemodialysis regimen

Up to 50 patients on hemodialysis >6 months, with stable target/dry weight, and have not been hospitalized recently

Device: Bioimpedance spectroscopy (BIS) measurement, SOZO device
All patients enrolled in this study will undergo BIS measurement before and after 12 hemodialysis sessions (pre-dialysis and post-dialysis BIS measurements for each session). Measurements are not provided to treating physicians and are not used to guide clinical decisions; i.e., BIS measurements are collected for observational purposes only.

Unstable hemodialysis regimen

Up to 20 patients who have been on hemodialysis <6 months, or have unintended weight loss/gain, or have recently been hospitalized

Device: Bioimpedance spectroscopy (BIS) measurement, SOZO device
All patients enrolled in this study will undergo BIS measurement before and after 12 hemodialysis sessions (pre-dialysis and post-dialysis BIS measurements for each session). Measurements are not provided to treating physicians and are not used to guide clinical decisions; i.e., BIS measurements are collected for observational purposes only.

Outcome Measures

Primary Outcome Measures

  1. BIS correlation with amount of fluid dialyzed [12 hemodialysis sessions (over 4 to 6 weeks)]

    BIS-measured fluid change (volume) will be analyzed for correlation with the volume of fluid removed during hemodialysis as documented on dialysis treatment records.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age >=18 years of age;

  2. End-stage renal disease with a GFR <15 mL/min/1.73m^2 and dialysis dependent requiring 3-times weekly dialysis;

  3. Able and willing to remove shoes and stand on SOZO for BIS measurements;

  4. Able to provide written informed consent and authorization to use and disclose health information.

Exclusion Criteria:
  1. Is enrolled in a concurrent interventional study of an experimental treatment that may confound the results of this study, in the investigator's opinion;

  2. Has a clinical condition that would not allow them to complete the study;

  3. Is pregnant or planning to become pregnant; women of childbearing potential (or premenopausal) must be on 2 forms of contraception;

  4. Is lactating;

  5. Has an implanted cardiac rhythm management device (pacemaker or implantable cardioverter defibrillator);

  6. Has an amputation of a limb/s resulting in them being unable to make contact with the SOZO electrodes (amputations of fingers and toes are not an exclusion);

  7. Patient determined by the attending physician unlikely to be compliant with study procedures.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Balboa Research - Kearny Mesa San Diego California United States 92111
2 Balboa Research - Rancho Bernardo San Diego California United States 92127

Sponsors and Collaborators

  • ImpediMed Limited
  • California Institute of Renal Research
  • Frenova Renal Research

Investigators

  • Principal Investigator: Mark Boiskin, MD, Balboa Research

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
ImpediMed Limited
ClinicalTrials.gov Identifier:
NCT05381961
Other Study ID Numbers:
  • IPD-ESRD-001
First Posted:
May 19, 2022
Last Update Posted:
May 19, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 19, 2022